Effect of Lactobacillus acidophilus & epidermal growth factor on experimentally induced Clostridium difficile infection

Indian Journal of Medical Research

Volumn 133, Issue 4, 2011, Pages 434-441

  Kaur, Sukhminderjit ^a   Vaishnavi, Chetana ^a   Prasad, Kaushal Kishor ^a   Ray, Pallab ^a   Kochhar, Rakesh ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Ampicillin; BALB c mice; Clostridium difficile; EGF; Lactobacillus acidophilus; Lansoprasole

Indexed keywords

AMPICILLIN; EPIDERMAL GROWTH FACTOR; LANSOPRAZOLE; MYELOPEROXIDASE; PROBIOTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVITY; HISTOPATHOLOGY; INOCULATION; LACTOBACILLUS ACIDOPHILUS; MALE; MICROBIAL COLONIZATION; MOUSE; NONHUMAN; TYPHLITIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AMPICILLIN; ANIMALS; CECUM; CLOSTRIDIUM DIFFICILE; COLON; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EPIDERMAL GROWTH FACTOR; ILEUM; LACTOBACILLUS ACIDOPHILUS; MICE; MICE, INBRED BALB C; PEROXIDASE; PROBIOTICS;

EID: 79955739439     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Senok AC, Rotimi VO. The management of Clostridium difficile infection: antibiotics, probiotics and other strategies. J Chemother 2008; 20: 5-13.
2. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20: 43-50.
3. Valiquette L, Low DE, Pépin J, McGeer A. Clostridium difficile infection in hospitals: a brewing storm. CMAJ 2004: 171:27-9.
4. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812-22.
5. Wullet M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhea: a double-blind placebo-controlled trial. Scand J Infect Dis 2003; 35: 365-7.
6. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhea. Int Microbiol 2004; 7: 59-62.
7. Elliott SN, Wallace JL, McKnight W, Gall DJ, Hardin JA, Oslon M, et al. Bacterial colonization and healing of gastric ulcers: the effects of epidermal growth factor. Am J Physiol GastrointestLiver Physiol 2000; 278: G105-12.
8. Kaur S, Vaishnavi C, Ray P, Kochhar R, Prasad KK. Effect of bio therapeutic s on cyclosporin-induced Clostridium difficile infection in mice. J Gastroenterol Hepatol 2010; 25: 832-8.
9. Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol 2007; 51: 1209-14.
10. Vaishnavi C, Kochhar R, Bhasin DK, Thapa BR, Singh K. Detection of Clostridium difficile toxin by an indigenously developed latex agglutination assay. Trop Gastroenterol 1999; 20: 33-5.
11. Bradely PP, Priebet DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with enzyme marker. J Invest Dermatol 1982; 78: 206-9.
12. Lowry OH, Rosebrough NJ, Fair AL, Randall RJ. Protein measurement with the folin phenol reagent. JBiol Chem 1951; 193: 265-75.
13. May T, Mackie RI, Garleb KA. Effect of dietary oligosaccharides on intestinal growth of and tissue damage by Clostridium difficile. Microecol Ther 1995; 23: 158-70.
14. Wilson KH, Sheagren JN, Fréter R, Weatherbee L, Lyerly D. Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. J Infect Dis 1986; 755:547-51.
15. Naaber P, Mikelsaar RH, Salminen S, Mikelsaar, M. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol 1998; 47: 591-8.
16. Vinderola G, Matar C, Perdigon G. Mlk fermentation products of L. helveticus R389 activate calcineurin as a signal to promote gut mucosal immunity. BMC Immunol 2007; 8: 19.
17. Black F, Einarsson K, Lidbeck A, Orrhage K, Nord CE. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment. Scand J Infect Dis 1991;25:247-54.
18. Gotz V. Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin associated diarrhoea with Lactobacillus preparation. Am J Hosp Pharm 1979; 36: 754-7.
19. Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfmkel JF. Double blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin- induced diarrhoea. Drug Interaction Clinical Pharmacy. Ann Pharm 1990; 24: 382-4.
20. Buret A, Oslon ME, Gall DJ, Hardin JA. Effects of orally administered epidermal growth factor on enteropathogenic Escherichia coli infection in rabbits. Infect Immun 1998; 66: 4917-23.
21. Riegler M, Sedivy R, Sogukoglu T, Castagliuolo I, Pothoulakis C, Cosentini E, et al. Epidermal growth factor attenuates Clostridium difficile toxin A- and B-induced damage of human colonic mucosa. Am JPhysiol 1997; 273: G1014-22.
22. Fallon JH, Serology KB, Loughlin SE, Morrison RS, Bradshaw RA, Knaver DJ, et al. Epidermal growth factor immunoreactive material in the central nervous system: location and development. Science 1994; 224: 1107-9.
23. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999; 5: 44-60.
24. Procaccino F, Reinshagen M, Hoffmann P, Zeeh JM, Lakshmanan J, McRoberts JA, et al. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology 1994; 107: 12-7.